Elicio Therapeutics Files 8-K on Shareholder Matters
Ticker: ELTX · Form: 8-K · Filed: May 20, 2025 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | May 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: ELIO
TL;DR
ELIO filed an 8-K for shareholder vote matters; check for updates on corporate actions.
AI Summary
Elicio Therapeutics, Inc. filed an 8-K on May 20, 2025, reporting on the submission of matters to a vote of security holders. The filing indicates a change in the company's reporting status and includes information about its corporate structure and previous name, Angion Biomedica Corp., which was changed on February 28, 2014.
Why It Matters
This filing signals important corporate actions or decisions requiring shareholder approval, which could impact the company's strategic direction and future performance.
Risk Assessment
Risk Level: low — The filing is procedural and relates to standard corporate governance, not immediate financial distress or significant operational changes.
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — Registrant
- Angion Biomedica Corp. (company) — Former company name
- May 19, 2025 (date) — Date of earliest event reported
- May 20, 2025 (date) — Date of report
- 001-39990 (other) — SEC File Number
FAQ
What specific matters were submitted to a vote of Elicio Therapeutics' security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 19, 2025.
What was Elicio Therapeutics, Inc. formerly known as?
Elicio Therapeutics, Inc. was formerly known as Angion Biomedica Corp.
On what date did the company change its name from Angion Biomedica Corp.?
The company changed its name from Angion Biomedica Corp. on February 28, 2014.
What is the principal executive office address for Elicio Therapeutics, Inc.?
The principal executive office address for Elicio Therapeutics, Inc. is 451 D Street, 5th Floor, Boston, Massachusetts 02210.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 20, 2025 regarding Elicio Therapeutics, Inc. (ELTX).